CO5160350A1 - Inhibidores de transferasa de proteina farnesilo - Google Patents

Inhibidores de transferasa de proteina farnesilo

Info

Publication number
CO5160350A1
CO5160350A1 CO99078843A CO99078843A CO5160350A1 CO 5160350 A1 CO5160350 A1 CO 5160350A1 CO 99078843 A CO99078843 A CO 99078843A CO 99078843 A CO99078843 A CO 99078843A CO 5160350 A1 CO5160350 A1 CO 5160350A1
Authority
CO
Colombia
Prior art keywords
alkyl
represent
halo
independently
present
Prior art date
Application number
CO99078843A
Other languages
English (en)
Spanish (es)
Inventor
Arthur G Taveras
Ronald J Doll
Alan B Cooper
Johan A Ferreira
Timothy Guzi
Alan K Mallams
Dinanath F Rane
Viyyoor M Girijavallab Rane
Adriano Afonso
J Cynthia Aki
Chao Jianping
Carmen Alvarez
Joseph M Kelly
Lalwani Tarik
A Desai Jagdish
James J-S Wang
Jay Weinstein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5160350A1 publication Critical patent/CO5160350A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO99078843A 1998-12-18 1999-12-16 Inhibidores de transferasa de proteina farnesilo CO5160350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
CO5160350A1 true CO5160350A1 (es) 2002-05-30

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99078843A CO5160350A1 (es) 1998-12-18 1999-12-16 Inhibidores de transferasa de proteina farnesilo

Country Status (20)

Country Link
EP (1) EP1140902A1 (enExample)
JP (1) JP2002533336A (enExample)
KR (1) KR20010081116A (enExample)
CN (1) CN1326850C (enExample)
AR (1) AR021718A1 (enExample)
AU (1) AU776558B2 (enExample)
BR (1) BR9916314A (enExample)
CA (1) CA2354779A1 (enExample)
CO (1) CO5160350A1 (enExample)
CZ (1) CZ20011950A3 (enExample)
HU (1) HUP0202152A2 (enExample)
IL (1) IL143408A0 (enExample)
NO (1) NO20012961L (enExample)
NZ (1) NZ511878A (enExample)
PE (1) PE20001342A1 (enExample)
PL (1) PL348293A1 (enExample)
SK (1) SK7592001A3 (enExample)
TR (1) TR200101755T2 (enExample)
WO (1) WO2000037459A1 (enExample)
ZA (1) ZA200104233B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
ZA985203B (en) * 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
PL348293A1 (en) 2002-05-20
IL143408A0 (en) 2002-04-21
SK7592001A3 (en) 2002-03-05
ZA200104233B (en) 2002-08-22
NZ511878A (en) 2003-10-31
CZ20011950A3 (cs) 2001-12-12
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
JP2002533336A (ja) 2002-10-08
AU776558B2 (en) 2004-09-16
HUP0202152A2 (en) 2002-10-28
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
BR9916314A (pt) 2001-10-02
CN1326850C (zh) 2007-07-18
PE20001342A1 (es) 2000-12-09
AU2030700A (en) 2000-07-12
NO20012961D0 (no) 2001-06-15
NO20012961L (no) 2001-08-16
CN1334811A (zh) 2002-02-06

Similar Documents

Publication Publication Date Title
CO5160344A1 (es) Inhibidores de transferasa de proteina farnesilo
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
SE7601205L (sv) Derivat av omettade aminosyror
CO5160350A1 (es) Inhibidores de transferasa de proteina farnesilo
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
AR090649A2 (es) Inhibidores del virus de la hepatitis c
AR004706A1 (es) Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo.
FI905770A0 (fi) Uusia isoindolonijohdannaisia niiden valmistus ja käyttö
CO5160250A1 (es) Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen
SE9100342D0 (sv) Novel steroid esters
CO6321266A2 (es) Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso
CO5261618A1 (es) Derivados de espiro [2h-1-benzopiran-2,4 -piperidina]
EA199800987A1 (ru) Бензоксазиноновые антагонисты рецептора допамина d4
SE7601207L (sv) Acetylenderivat av acetyleniska aminosyror
CO4950561A1 (es) Derivados de ergolina
CO4960656A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-1-ilmetil)1h- indol
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
AR068425A1 (es) Metodo de alimentacion de cerdos con compuestos de glicina
DK217281A (da) Fremgangsmaade til fremstilling af 4-hydroxy-3-quinolincarboxylsyrederivater
PE20081139A1 (es) Derivados de cromano, su sintesis e intermediarios
AR047274A1 (es) Derivados de oxazoltetraciclinas como antibioticos. metodos de obtencion y composiciones farmaceuticas.
AR048644A1 (es) Derivados del indol como moduladores selectivos de los receptores androgenicos (sarms)